Essex Bio-Tech Adds 7,000 Shares to Treasury, Total Buybacks Reach 2.13 Million

Hong Kong-listed Essex Bio-Technology Limited disclosed a modest on-market share repurchase in a Next Day Disclosure Return filed on 06 October 2026.

On 06 October 2026 the company bought back 7,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging between HKD 2.075 and HKD 2.105 per share, representing a volume-weighted average purchase price of approximately HKD 2.10. The aggregate consideration for the transaction was HKD 14,685.

Following the repurchase, Essex Bio-Tech’s issued share capital (excluding treasury shares) decreased by 0.00124 % to 564.88 million shares, while treasury shares increased to 2.13 million. The company’s total issued share count remained unchanged at 567.01 million shares.

The buyback was executed under the general mandate approved by shareholders on 26 May 2026, which authorises repurchases of up to 56.70 million shares. To date, Essex Bio-Tech has repurchased 2.13 million shares under this mandate, equivalent to 0.38 % of the share capital outstanding on the mandate’s approval date.

In accordance with Hong Kong Stock Exchange rules, the company confirmed that the transaction was duly authorised, funds were fully settled, and all regulatory requirements were met. A moratorium on new share issues or sales of treasury shares is in place until 05 November 2026.